Korro Bio, Inc. KRRO 深 沪
已收盘 02-06 16:00:00 美东时间
12.57
+1.030
+8.93%
华盛通- 最 高12.78
- 今 开11.64
- 成交量 18.47万股
- 最 低 11.64
- 昨 收 11.54
- 总市值 1.18亿
- 52周最高 55.89
- 市盈率 静 --
- 换手率 1.96%
- 52周最低 5.2044
- 委 比 0.99%
- 总股本 941.73万
- 历史最高 2918.50
- 量 比 0.88
- 振 幅 9.88%
- 历史最低 5.2044
- 每 手 1
- 风险率 11.34%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | Meta 、IBM、拉姆研究、布林克国际等获多家机构上调目标价；微软、特斯拉、ServiceNow、自动数据处理等遭多家下调评级
今日重点评级关注：Piper Sandler：上调Korro Bio评级至"超配"，目标价从11美元升至30美元；Piper Sandler：维持Nurix Therapeutics"超配"评级，目标价从32美元升至35美元
01-30 17:38
This Fortinet Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Top Wall Street analysts changed their outlook on these top names. For a comple...
01-29 20:41
美股大行评级 | 希捷科技、德州仪器、HCA控股、通用汽车、波音、UPS等或多家机构上调目标价；布朗保险、康沃系统、Qorvo、联合健康等遭多家机构下调目标价
今日重点评级关注：Piper Sandler：维持Praxis Precision Medicine"超配"评级，目标价从450美元升至1200美元；Tigress Financial：维持Main International ETF"买入"评级，目标价从52美元升至66美元
01-29 11:06
Cantor Fitzgerald Upgrades Korro Bio to Overweight, Announces $21 Price Target
Cantor Fitzgerald analyst Steve Seedhouse upgrades Korro Bio (NASDAQ:KRRO) from Neutral to Overweight and announces $21 price target.
01-28 23:08
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers ENvue Medical (NASDAQ:FEED) stock moved upwards by 19.0% to $1.25 duri...
01-28 20:05
美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
2025-11-14 10:43
Cantor Fitzgerald Downgrades Korro Bio to Neutral
Cantor Fitzgerald analyst Steve Seedhouse downgrades Korro Bio (NASDAQ:KRRO) from Overweight to Neutral.
2025-11-13 21:28
Korro Bio Announces 34% Workforce Reduction To Extend Cash Runway Into Second Half Of 2027 To Provide Sufficient Capital To Deliver Clinical Data From KRRO-121; Estimates That It Will Incur One-time Restructuring Charges Of ~$2.4M
Approximately 34% reduction in workforce impacting all levels of the organization.
2025-11-13 05:51
Korro Bio Q3 EPS $(1.92) Beats $(2.59) Estimate, Sales $1.090M Beat $578.222K Estimate
Korro Bio (NASDAQ:KRRO) reported quarterly losses of $(1.92) per share which beat the analyst consensus estimate of $(2.59) by 25.98 percent. This is a 15.04 percent increase over losses of $(2.26) per share from the
2025-11-13 05:46
美股大行评级 | 苹果、亚马逊、Cloudflare、西部数据、Twilio等获十多家机构集体上调目标价；杰富瑞首予Cloudflare"持有"评级，目标价250美元
今日重点评级关注：康托·菲茨杰拉德：维持Cabaletta Bio"超配"评级，目标价从15美元升至30美元；HC Wainwright & Co.：维持Invivyd"买入"评级，目标价从5美元升至10美元
2025-11-03 20:20
